Alternatively, strategies forcing the expression of MAT1A in liver cancer, instead of directly treating with SAMe, were shown to reduce HCC growth and angiogenesis, and increase apoptosis in in vitro and in vivo models [250]. This evidence concerns the gene MAT1A and hepatocellular carcinoma.